Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | AGXT | P21549 | 2/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1047547 | 0.94 | TAAR1 (0.57) | TAAR1SIGMAR1IDO1AGXTCYP4F2 | |
| SCHEMBL1045131 | 0.92 | TAAR1 (0.55) | TAAR1SIGMAR1IDO1AGXTCYP4F2 | |
| SCHEMBL3456345 | 0.92 | TAAR1 (0.55) | TAAR1SIGMAR1IDO1AGXTCYP4F2 | |
| SCHEMBL643177 | 0.87 | TAAR1 (0.63) | TAAR1IDO1AGXTCYP4F2CYP4A11 | |
| SCHEMBL5240585 | 0.87 | TAAR1 (0.68) | TAAR1SIGMAR1IDO1AGXTMAOB | |
| SCHEMBL19524669 | 0.85 | TAAR1 (0.65) | TAAR1SIGMAR1IDO1AGXTMAOB | |
| SCHEMBL241880 | 0.84 | CYP4F2 (0.53) | TAAR1CYP4F2CYP4A11 | |
| SCHEMBL4399626 | 0.82 | TAAR1 (0.74) | TAAR1SIGMAR1IDO1AGXTMAOB | |
| Alcohol SCHEMBL7528524 | 0.82 | TAAR1 (0.57) | TAAR1IDO1AGXTCYP4F2CYP4A11 | |
| SCHEMBL82275 | 0.81 | TAAR1 (0.61) | TAAR1SIGMAR1IDO1AGXTMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2000037425-A1 | METHOD FOR PRODUCING FLUOXETIN | SIEGFRIED CMS AG (CH) | 2000-06-29 | — | — | WO | claimed |
| US-20250248975-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SCHRODINGER, LLC | 2025-08-07 | — | — | US | disclosed |
| US-20240246992-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | SERVIER LAB (FR) | 2024-07-25 | — | — | US | disclosed |
| WO-2024054851-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USING THEREOF | SIONNA THERAPEUTICS (US) | 2024-03-14 | — | — | WO | disclosed |
| US-11919839-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | VALO HEALTH, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| EP-4308570-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | Les Laboratoires Servier (FR) | 2024-01-24 | — | — | EP | disclosed |
| CN-117425661-A | Macrocyclic LRRK2 kinase inhibitors | 法国施维雅药厂 | 2024-01-19 | — | — | CN | disclosed |
| EP-4276092-A1 | COMPOUND LIBRARY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-15 | — | — | EP | disclosed |
| EP-4276092-A1 | COMPOUND LIBRARY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-15 | — | — | EP | disclosed |
| CN-116783160-A | Libraries of compounds | 中外制药株式会社 | 2023-09-19 | — | — | CN | disclosed |
| CN-1117291-A | 4-Hydroxy-pyran-2-one derivatives for the treatment of retroviral infections | UPJOHN CO (US) | 1996-02-21 | — | — | CN | disclosed |
| WO-1995034540-A1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-12-21 | — | — | WO | disclosed |
| EP-0682663-A1 | 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1995-11-22 | — | — | EP | disclosed |
| EP-0536713-A1 | Oxazole and imidazole derivatives as prostaglandin analogs | E.R. SQUIBB & SONS, INC. (US) | 1993-04-14 | — | — | EP | disclosed |
| EP-0077651-A2 | Method of producing alpha, gamma-halohydrins and uses of the same | CETUS CORPORATION (US) | 1983-04-27 | — | — | EP | disclosed |
| US-4195178-A | Methylenecyclopentane derivatives | THE UPJOHN COMPANY (US) | 1980-03-25 | — | — | US | disclosed |
| US-4181798-A | Methylenecyclopentane derivatives | THE UPJOHN COMPANY (US) | 1980-01-01 | — | — | US | disclosed |
| US-4175202-A | 4,5,6-Trinor-3,7,-inter-m-phenylene prostaglandin A1 analogs | THE UPJOHN COMPANY (US) | 1979-11-20 | — | — | US | disclosed |
| US-4100192-A | Inter-phenylene-PG amides | THE UPJOHN COMPANY (US) | 1978-07-11 | — | — | US | disclosed |
| US-4084058-A | HYPOTENSIVES, ANTICOAGULANTS | THE UPJOHN COMPANY (US) | 1978-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246992-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | LRRK2, PARK7, PINK1 | TAAR1 4210/4885SIGMAR1 3632/4885IDO1 4094/4885 |
| US-11919839-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | HDAC8, HDAC7, HDAC1 | TAAR1 4378/4885SIGMAR1 4114/4885IDO1 3723/4885 |
| US-20250248975-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | CFTR, ABCB1, PKD1 | TAAR1 4778/4885SIGMAR1 1136/4885IDO1 4799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.